Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311845 | 0.93 | NPC1 (0.42) | RXFP1PTGESPDE2APDE10AMEN1 | |
| SCHEMBL13165374 | 0.87 | NPC1 (0.44) | RXFP1PTGESPDE2APDE10AMEN1 | |
| SCHEMBL2348112 | 0.83 | NPC1 (0.41) | RXFP1PTGESPDE2APDE10AKMT2A | |
| SCHEMBL3311654 | 0.83 | PTGES (0.39) | RXFP1PTGESPDE2APDE10AMEN1 | |
| SCHEMBL68893 | 0.79 | NPC1 (0.47) | PDE2APDE10AMEN1KMT2ANPSR1 | |
| SCHEMBL3310669 | 0.78 | KDM4E (0.37) | RXFP1PTGESPDE2APDE10AMEN1 | |
| SCHEMBL3309386 | 0.78 | GAA (0.38) | PTGESPDE2APDE10AKMT2AKDM4E | |
| SCHEMBL3311229 | 0.76 | RAPGEF4 (0.35) | MEN1KMT2ALMNASMN1; SMN2NPC1 | |
| SCHEMBL3334028 | 0.75 | SMN1; SMN2 (0.45) | PTGESPDE2APDE10AKDM4ENPSR1 | |
| SCHEMBL29369509 | 0.75 | NPC1 (0.44) | PDE2APDE10AMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | claimed |
| EP-2121629-A1 | NOVEL PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | claimed |
| CN-101541763-A | Novel pyridazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | CN | claimed |
| WO-2008049584-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | claimed |
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2121629-A1 | NOVEL PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| CN-101541763-A | Novel pyridazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | CN | disclosed |
| WO-2008049584-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | C3AR1, C5, C1S | RXFP1 2667/4885PTGES 1929/4885PDE2A 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.